GO
Loading...

Squawk Box

More

  • S&P 500 target 1,950: Expert     Thursday, 24 Apr 2014 | 6:37 AM ET

    Michael Ryan, UBS, takes a look at the quality of first quarter earnings and the outlook on the S&P 500 this year. At the end of the day it's about corporate profits and earnings, says Ryan.

  • Apple beats the Street     Thursday, 24 Apr 2014 | 6:19 AM ET

    Dan Morgan, Synovus Trust, shares his thoughts on Apple's new products and 7-for-1 stock split.

  • GE in talks to buy Alstom: Report     Thursday, 24 Apr 2014 | 6:09 AM ET

    Nicholas Heyman, William Blair, discusses General Electric's possible acquisition of French train and power plant builder Alstom for more than $13 billion.

  • My Herbalife short is looking much better: Ackman Wednesday, 23 Apr 2014 | 12:09 PM ET
    An employee carries a box of products for shipment to a truck at the Herbalife Los Angeles distribution center in Carson, Calif.

    Bill Ackman tells CNBC that his losses from betting against Herbalife have been "more than cut in half" based on the recent downturn of the company's stock.

  • Too many Dunkin' Donuts?     Wednesday, 23 Apr 2014 | 8:55 AM ET

    Dunkin' Brands plans to have 1,000 stores in the Golden State, reports CNBC's Jane Wells with a look at the company's expansion plans.

  • Cramer: It wasn't front running     Wednesday, 23 Apr 2014 | 8:45 AM ET

    CNBC's Jim Cramer shares his thoughts on the legality of Bill Ackman's deal with Valeant to acquire Allergan, and why the SEC has an "existential crisis."

  • Will shareholders KO compensation plan?     Wednesday, 23 Apr 2014 | 8:32 AM ET

    Jason Subotky, Yacktman Funds, shares his thoughts on Coca-Cola's equity compensation plan. The problem with these plans are they are complicated and a lot of the details are not fully flushed out, says Subotky.

  • I did not front-run Allergan stock, Ackman says Wednesday, 23 Apr 2014 | 9:40 AM ET
    Bill Ackman

    Bill Ackman also tells CNBC that Allergan's poison-pill defense doesn't make his takeover bid more difficult.

  • Facebook is our top pick for 2014: Analyst     Wednesday, 23 Apr 2014 | 8:12 AM ET

    Anthony DiClemente, Nomura senior analyst, shares his upbeat outlook on the social media giant, as advertising dollars continue to shift towards digital media.

  • AT&T transforming customer base: CFO     Wednesday, 23 Apr 2014 | 8:04 AM ET

    John Stephens, AT&T CFO, delves into Ma Bell's quarterly numbers and weighs in on the company's strategy to increase its wireless subscribers.

  • William Ackman, Pershing Square Capital Management, explains how his partnership with Valeant is structured. And J. Michael Pearson, Valeant chairman & CEO, discusses why he partnered with Ackman instead of pursing Allergan alone. Creating shareholder value is our job, says Pearson.

  • Ackman: Allergan clear fit for Valeant     Wednesday, 23 Apr 2014 | 7:41 AM ET

    William Ackman, Pershing Square Capital Management, explains why he is helping Valeant buy Allergan.

  • J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, weighs in on news that Allergan has adopted a "poison pill" defense strategy. Also Pearson shares his thoughts on adding some of Allergan's notable cosmetic products like Botox and Restasis to its growing arsenal.

  • Valeant CEO: Allergan has a great set of assets     Wednesday, 23 Apr 2014 | 7:33 AM ET

    J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, explains why he decided to pursue Allergan and shares his R&D business model, with CNBC's Kate Kelly. This year we are launching 19 products in the United States, says Pearson.

  • Ackman: Valeant fit into Pershing investing mold     Wednesday, 23 Apr 2014 | 7:32 AM ET

    William Ackman, Pershing Square Capital Management, explains why he decided to team up with Valeant Pharmaceuticals to make a play for Allergan.

  • Boeing Q1 beats on top and bottom line     Wednesday, 23 Apr 2014 | 7:30 AM ET

    Boeing's profit margin on the commercial side improves to 11.8 percent, reports CNBC's Phil LeBeau with a break down on Boeing's quarterly results.

  • P&G Q3 profit rises     Wednesday, 23 Apr 2014 | 7:17 AM ET

    Jon Moeller, Procter & Gamble CFO, breaks down the company's third quarter results of $1.04 EPS ex-items on revenues of $20.56 billion and weighs in on where the company sees global growth.

  • Dow CEO: We engage activist investors     Wednesday, 23 Apr 2014 | 7:11 AM ET

    Most of these investors are looking for a dialogue to improve value, says Andrew Liveris, President, Chairman & CEO of Dow Chemical, sharing his thoughts on activist investors.

  • Dow Chemical reports Q1 earnings beat     Wednesday, 23 Apr 2014 | 7:03 AM ET

    We overcame transport and weather issues in North American, says Andrew Liveris, President, Chairman & CEO of Dow Chemical, breaking down his company's first quarter results of $0.79 EPS on revenues of $14.46 billion.

  • Yummie: Not your grandma's girdle anymore     Wednesday, 23 Apr 2014 | 6:50 AM ET

    It's not a dirty little secret anymore, says Heather Thomson, Yummie by Heather Thomson founder, discussing how her company is redefining the shapewear industry and carving out a piece of the market.

About Squawk Box

  • "Squawk Box" is the ultimate "pre-market" morning news and talk program, where the biggest names in business and politics tell their most important stories. Anchored by Joe Kernen, Becky Quick and Andrew Ross Sorkin, the show brings Wall Street to Main Street. It's a "must see" for everyone from the professional trader to the casual investor.

Contact Squawk Box

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More
  • Showtimes

    U.S.
    Weekdays 6a ET
    EMEA
    Weekdays 13:00 CET
    Asia
    Weekdays 18:00 SIN/HK
    Australia
    Weekdays 20:00 SYD
    New Zealand
    Weekdays 22:00 NZ

 

  • Joe Kernen is co-anchor of "Squawk Box," CNBC's signature morning program.

  • "Squawk Box" Co-Anchor

  • Andrew Ross Sorkin is a co-anchor of "Squawk Box," a financial columnist for "The New York Times" and the editor-at-large of NYT's DealBook.